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Abstract 
PROTEASE INHIBITOR THERAPY IN HIV-INFECTED CHILDREN 
Naomi L. Katz, Michael B. Bracken, and Warren A. Andiman. Section of Pediatric 
Infectious Diseases, Department of Pediatrics, Yale University School of Medicine, New 
Haven, CT. 
While protease inhibitors (Pis) have been found to dramatically decrease viral burden and increase 
CD4+ T-cells in adults infected with human immunodeficiency virus (HIV), studies in children have been 
limited. This study was designed to assess the effect of Pis on viral load and CD4+ T-cell count in a cohort 
of 79 HIV-infected children followed for a mean of 24 months, and to determine the effect of prior 
antiretroviral exposure on the success of PI therapy. Subjects were classified as either PI or non-PI treated. 
There were no significant differences overall between the PI and non-PI treated groups with respect to 
changes in viral load, CD4+ T-cell count, and CD4+ T-cell percent, after controlling for baseline values. 
The Pl-treated group was subdivided into a “dual therapy” group and a “triple therapy” group, based on 
medication regimen just prior to PI initiation. The “dual therapy” group was found to have a faster rate of 
achieving a significant drop in viral load than the “triple therapy” group after initiating Pis (54% versus 
14% at 12 months, p=0.05), which was independent of baseline viral load and more likely affected by 
previous antiretroviral exposure. The “triple therapy” group was found to have a faster rate of achieving a 
significant rise in CD4+ T-cell count than the “dual therapy” group after initiating Pis (100% versus 53% at 
12 months, p=0.03), which appeared to be due to a higher baseline CD4+ T-cell count. In conclusion, 
although there was no overall improvement in subjects treated with Pis over a long term follow-up, there 
was a trend toward improved immune status in the PI treated subjects. In addition, subjects who had less 
antiretroviral experience and higher immune status at baseline had a more rapid response to Pis. This study 
supports the use of Pis in HIV-infected children early in the disease course to provide maximal immune 
reconstitution. 
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Introduction 
Epidemiology 
The burden of human immunodeficiency virus type 1 (HIV-1) infection in the 
pediatric population has been increasing, paralleling the rise in HIV among women. One 
million infants and children worldwide are thought to be infected with HIV (1). It was 
estimated that in the United States more than 16,300 children were perinatally infected 
with HIV through 1995 (2). It was predicted that another 1,500 HIV-infected children 
would be born by the end of 1997. More than 7,900 children in the U.S. with acquired 
immunodeficiency syndrome (AIDS) have been reported to the Centers for Disease 
Control and Prevention (CDC) as of the end of 1997 (3). There is still no cure or vaccine 
for this fatal disease. 
However, children are now living longer with HIV, due mainly to the advent of new 
and more effective therapies. Mortality from HIV has fallen from the 8th leading cause 
of death in children in 1995 to the 14th in 1997 (4). Since 1995, mortality from HIV 
infection has fallen by 62%. From 1996 to 1997 alone, the death rate from HIV infection 
decreased by 47% (4). Currently, between 36% and 61% of infected children are 
estimated to survive to age 13 and the median survival time is 12.7 years (5). These 
therapeutic advances have resulted not only in this dramatic reduction in mortality but 
also a delay in progression to AIDS. Two-thirds of surviving HIV-positive children older 
than age 5 have not yet been diagnosed with AIDS (5). 
Initially, children represented a group of low incidence of infection within the HIV 
epidemic. Thus, there has not been much information on the natural history of the 
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disease in children. In addition, children were originally excluded from clinical trials due 
to safety concerns and thus, in comparison to adults, there have been relatively few 
studies of the safety and efficacy of antiretroviral medications in pediatric patients. Many 
of the antiretroviral medications that have been found to be effective in controlling 
disease progression in adults are only recently being studied in children. 
The natural history of HIV may have a very different course among children than 
among adults. It has been hypothesized that it is not possible to extrapolate guidelines 
from adult natural history and therapeutic trials to the pediatric population for the 
following reasons: first, high plasma levels of virus in infancy persist through the first 2 
to 3 years of life before reaching a lower steady state level; and, second, infection is 
established within a developmentally immature immune system (6, 7). More rapid 
disease progression has been observed in perinatally infected infants than in children 
infected at older ages and in adults, due in part to their inferior immune systems (8). In 
addition, treatment of perinatally infected children often occurs in the context of previous 
exposure to zidovudine and other antiretroviral agents given to the mother during 
pregnancy and to the baby during the neonatal period, raising the possibility of resistant 
strains (9). The increased rate of disease progression in children suggests that the higher 
viral loads may be comprised of more virulent strains. The mean time to a CDC Class C 
diagnosis (see Appendix 4) is 4 to 6 years in children, compared with 10 years in adults 
(10). Therefore, it is necessary to examine the clinical and prognostic factors specific to 
pediatric patients and to develop treatment guidelines unique to this population. 
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Antiretroviral therapy 
It is a generally held principle that the goal of antiretroviral therapy in adults is 
maximal suppression of viral replication (11). Currently, the recommended initial 
regimen for infected adults is combination therapy, or highly active antiretroviral therapy 
(HAART), that includes two nucleoside analog reverse transcriptase inhibitors (NRTIs) 
and one protease inhibitor (PI) (9). Based on adult data, similar guidelines have informed 
the recommendations for initial regimens in children (see Appendix 1) (12, 13). Because 
children often maintain higher viral burdens and thus have the potential to develop 
resistance more frequently, it is recommended that potent combination antiretroviral 
regimens be used early, in order to maximally control viral replication, minimize the 
development of resistance, and preserve immune function (9, 13). Palumbo et al. found a 
reduced risk of HIV disease progression for each logl0 reduction in baseline viral load (6). 
This risk reduction was linear, without a threshold or age effect, supporting the theory 
that maximal viral load suppression is the optimal goal. 
However, there has been minimal experience with PI therapy in children. Based on 
these limited data, the FDA, to date, has approved ritonavir and nelfinavir for use in 
children older than 2 years of age (12). Ritonavir is available in liquid formulation and 
nelfinavir is available in powder formulation that can be mixed with food or water. 
Saquinavir and indinavir are not yet available in pediatric formulations. 
Most of the studies of PI therapy in children have been retrospective studies with 
small numbers of subjects and short-term follow-up (14-19). Preliminary results have 
shown that PI therapy results in decreases in HIV RNA levels and increases in CD4+ T- 
lymphocyte counts; however, many of these studies have not included a control group for 

comparison. The efficacy of PI therapy in children remains unclear, particularly over 
periods of time longer than 6 months. 
4 
The optimal timing of initiation of protease inhibitor therapy has also not been 
adequately studied in children. Changes in antiretroviral therapy are recommended for 
the following reasons: failure of current regimen with evidence of disease progression 
based on virologic, immunologic, or clinical parameters; toxicity or intolerance to current 
regimen; and new data demonstrating superiority of a drug or regimen over the current 
regimen (13). Because the therapeutic goal is generally maximal suppression of viral 
load, use of highly active antiretroviral therapy (HAART), which includes protease 
inhibitors, has become standard in children. 
Most patients who are started on PI therapy will have been exposed previously to 
multiple other antiretrovirals. It remains unclear whether PI therapy should be initiated 
early in the disease course, prior to development of viral resistance, or late, following 
maximal use of other regimens. Early treatment with Pis may provide more substantial 
suppression of viral load at an earlier stage in the infection. However, this would limit 
options later if viral resistance were to develop. Conversely, later use of Pis may limit 
their efficacy if resistant viral strains have already developed. 
In a study of adults who were started on HAART, individuals without prior 
antiretroviral exposure had better responses than those with prior exposure (20). Among 
subjects who were treatment-naive prior to PI therapy, 91% reached an undetectable viral 
load (<400 copies/mL) by 12 months. Among the patients who had been exposed to 
other antiretrovirals, a range of 70% to 79% reached an undetectable viral load, 
dependent on prior drug exposure. Viral rebound (defined as two consecutive viral load 
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measurements of > 400 copies/mL) occurred in 36% to 40% of pretreated individuals, 
dependent on their prior exposure, but in only 20% of treatment-nai've individuals. 
Disease progression, as defined by occurrence of an AIDS defining event or death, was 
also reduced in those who achieved and maintained undetectable viral loads. The study 
found HAART to be moderately successful in suppressing viral replication, increasing 
CD4+ T-cell count, and slowing disease progression. There was a lower probability of 
achieving viral suppression in patients who had been previously treated with reverse- 
transcriptase inhibitors. The authors suggested that their findings were a result of 
sequential initiation of antiretroviral drugs which impairs efficacy because of failure to 
overcome drug-resistant mutations. This supports the theory that Pis should be initiated 
early, prior to the development of resistance. The authors also found a paradoxically 
greater increase in CD4+ T-cell count after initiating PI therapy in those with higher 
baseline viral load. To date, there have not been any studies that have examined the 
efficacy of Pis in children in the context of previous medication history. 
Monitoring surrogate markers of infection 
The prognostic value of viral load levels and CD4+ T-lymphocyte counts have yet 
to be determined in the pediatric population. Higher HIV RNA levels have been shown, 
in general, to be correlated with disease progression and death. However, viral RNA 
levels overlap considerably among infants who have rapid disease progression and those 
who do not, suggesting that factors other than viral replication play a role in the natural 
history of HIV disease in this population (9). 
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CD4+ T-cell counts have been found to be age-dependent, thus the absolute number 
which identifies a specific level of immune suppression varies with age (9). However, 
the CD4+ T-cell percentage which defines CDC immunologic categories does not change 
with age and thus may be a better prognostic marker for disease progression (13). In 
addition, it has been hypothesized that zidovudine may affect T-cells directly both by 
promoting T-cell proliferation and apoptosis. The net effect of this dual action is that the 
numbers of circulating T-cells may be normal but immune function compromised in 
zidovudine-treated individuals (21). Thus there may not be an absolute correlation 
between levels of CD4+ T-cells and response to therapy. These uncertainties must be 
considered when assessing the efficacy of antiretroviral medications. 
Mechanism of action of protease inhibitors 
Protease inhibitors cause an initial decrease in viral load levels and a subsequent 
increase in immune function. Pis exert their action by inhibiting the enzyme protease, 
which is responsible for cleavage of viral polyproteins into smaller, functional proteins 
(12). Thus, the virion is unable to mature and is rapidly cleared. One advantage of Pis 
over other antiretrovirals is their ability to reduce the production of infectious particles in 
chronically infected cell lines, which may constitute a major reservoir for HIV. This 
contrasts with the reverse transcriptase inhibitors, which inhibit HIV replication only in 
newly-infected cells (11, 12). Thus, combinations of Pis and nucleoside and 
nonnucleoside reverse transcriptase inhibitors appear to be additive and oftentimes 
synergistic. 
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Side effects observed with PI therapy include gastrointestinal symptoms such as 
nausea, vomiting and diarrhea. Renal calculi have also been reported, most often with 
indinavir (12). Some patients exhibit elevations in liver transaminases, alkaline 
phosphatase, fasting triglyceride, and cholesterol levels (15). In addition, there have been 
reported associations with new onset diabetes mellitus, exacerbation of existing diabetes 
mellitus, and hyperglycemia (9). 
Studies have shown that high rates of viral replication contribute to the emergence 
of drug resistant variants. Mutations within the protease gene confer resistance to Pis by 
causing amino acid substitutions at various positions in the protease enzyme (12). The 
mutations which occur with Pis are more numerous and complex than those associated 
with nucleoside and nonnucleoside reverse transcriptase inhibitors and they overlap 
among different Pis, causing reduced susceptibility to other Pis once resistance to one 
drug develops (9). 
The frequency of mutations and the success of Pis greatly depends on adherence to 
medication dosing schedules. Children have unique adherence issues which must be 
considered in decisions concerning antiretroviral therapy. Children are generally 
dependent on a parent or other caregiver for administering the medication, necessitating 
proper education of both the child and the caregiver. Tiquid formulations or formulations 
which can be mixed with formula or food are necessary for young children. Side effects 
and lack of palatability can also affect compliance in children. In addition, the desire for 
confidentiality may limit adherence to regimens in children when away from home, such 
as during school hours. Noncompliance and subtherapeutic levels of protease inhibitors, 

in particular, can lead to treatment failure (22). Thus the risks and benefits of these 
medications in children must be carefully assessed. 
Specific aims 
The purpose of this study was to analyze retrospectively the effects of PI therapy on 
certain surrogate markers of infection known to have prognostic significance. The first 
part of the study was designed to compare pediatric subjects who received Pis as part of 
their therapy to those who never received PI therapy. The hypothesis was that patients 
treated with protease inhibitors would exhibit a greater reduction in viral load and a 
greater increase in CD4+ T-lymphocyte count and CD4+ percentage than patients not 
treated with protease inhibitors. 
The second part of the study was designed to assess the effect of prior medication 
history on the success of PI therapy. Patients who were started on Pis after having 
previously received no therapy, monotherapy or dual therapy were compared with those 
who were started on PI therapy after having received triple therapy. The secondary 
hypothesis was that patients who were relatively treatment-inexperienced, (i.e. no 
therapy, monotherapy or dual therapy) would more likely achieve a reduction in viral 
load and a rise in CD4+ T-lymphocyte count once started on protease inhibitors than 
those who were more treatment-experienced (i.e. triple therapy). 
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Methods 
Study population 
This was a retrospective cohort study. The study population was comprised of 79 
HIV-infected pediatric patients who were followed at the Pediatric Immunology Clinic at 
Yale-New Haven Hospital. All patients had been infected with HIV perinatally. Visits to 
the clinic and changes in medication regimen were determined by the clinic practitioners, 
based on the clinical status of the patient. Laboratory evaluations performed on all 
patients included HIV RNA plasma levels (viral loads), absolute CD4+ T-cell counts and 
percentages. Medication regimens and CDC clinical category were revised and recorded 
regularly. The database included measurements from December 13, 1995 through June 
1, 1999. Subjects were included who had baseline viral load and CD4+ T-cell count 
measurements at the time of initiation of protease inhibitor therapy and who also had at 
least one follow-up measurement of viral load and CD4+ T-cell count recorded after PI 
therapy was begun. 
The study was approved by the Human Investigation Committee of Yale University 
School of Medicine and Yale-New Haven Hospital, New Haven, Connecticut. 
Study measures 
Blood samples from each patient were collected for viral load and CD4+ T- 
lymphocyte counts. Plasma HIV-1 RNA levels were quantified using the Roche 
Amplicor® polymerase chain reaction reverse transcriptase assay (Roche Diagnostic 
Systems). Viral load measures were also reported as the log of the viral load (log,o copies 
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HIV RNA/mL). Absolute CD4+ T-lymphocyte cell counts (cells/pL) and cell 
percentages (%) were measured using fluorescent absortiometry cell sorting analysis. All 
medication regimens were recorded and coded. HIV clinical category was determined by 
the medical practitioners in the Yale Pediatric Immunology Clinic using the 1994 CDC 
classification system and recorded at each clinic visit (see Appendices 2-4). 
The first part of the analysis was designed to compare subjects with respect to the 
overall change in viral load and CD4+ T-cell count during the study period. The 
independent variable was whether the patient had or had not been treated with PI therapy. 
The study group was comprised of all subjects who had ever been treated with PI therapy. 
The control group was comprised of subjects who had never been treated with Pis. 
Subjects who were treated with Pis for less than three weeks were considered not to have 
been treated with Pis, in order to ensure that each member of the study group had 
sufficient exposure to PI therapy to produce a potential effect. The independent variable 
was analyzed as a dichotomous variable. 
The main outcomes of interest were changes in the log of viral RNA levels, 
absolute CD4+ T-cell count, and CD4+ T-cell percentage. For those in the PI group, the 
difference in viral RNA level was assessed to be the final recorded measurement minus 
the baseline measurement on the day that PI therapy was initiated. For the non-PI group, 
the difference was calculated as the final measurement minus the first measurement 
recorded during the study period. These differences were analyzed as continuous 
variables. 

Covariables examined included age, baseline viral load, baseline absolute CD4+ T- 
cell count, baseline CD4+ T-cell percentage, and duration of therapy. All covariables 
were analyzed as continuous variables. 
All subjects who had been treated with Pis were further divided into two groups, 
based on their medication history. Subjects were defined as “treatment inexperienced” if 
they had been treated with no therapy, monotherapy (always a NRTI), or dual therapy at 
the visit just prior to the initiation of Pis. The most common dual therapy regimens 
included zidovudine/lamivudine and lamivudine/stavudine. Subjects were defined as 
“treatment experienced” if they had been on triple therapy just prior to the initiation of 
Pis. Some of the most common triple therapy regimens included 
zidovudine/didanosine/nevirapine, zidovudine/didanosine/stavudine, or 
lamivudine/stavudine/nevirapine. 
The outcome measures assessed were changes in viral load and absolute CD4+ T- 
cell count. A virological response was defined as a decrease in viral load of > 0.5 log. A 
CD4+ T-cell response was defined as an increase of > 50 cells/pL. The date of the first 
measurement meeting these definitions was used in the analysis. If the subject did not 
reach these endpoints, the date of the most recent clinic visit was used and the data were 
censored. 
The date of achieving an undetectable viral load was designated as midway between 
the last detectable measurement and the first undetectable measurement. The number of 
weeks between the start of PI therapy and the date of achieving undetectable levels was 
calculated to be the length of time to undetectable viral load. 

Statistical analysis 
All analyses were performed using the Statistical Analysis Software® (SAS) 
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package, version 6.12. Univariate analyses were performed on all independent variables, 
dependent variables, and covariables. Bivariate analyses performed included t-tests and 
Pearson correlation coefficients. T-tests were performed to examine the association 
between the main independent variable (PI therapy) and all outcomes and covariables. 
Pearson correlation coefficients were performed to analyze the association between 
covariables and outcomes. Multiple linear regression was used to identify the variables 
which predicted differences in viral load, absolute CD4+ T-cell count, and CD4+ T-cell 
percentage. A separate model for each outcome was constructed using a backward 
selection process. Variables were retained which were significant at the 0.20 level. 
Assumptions for linearity, homoscedasticity, and normality were satisfied. 
Linearity was assessed by categorizing all covariables into quartiles, calculating the mean 
of each outcome within the categories, and examining plots of categorized covariables 
versus mean outcomes. Homoscedasticity was assessed by inspecting plots of residuals, 
which exhibited no clear patterns. Normality was assessed by examining the normal 
probability plots for each variable. There was no evidence for collinearity among 
covariables, as all Pearson correlation coefficients were low. 
Kaplan-Meier life-tables were used for time-to-event analysis. Initial viral load and 
absolute CD4+ T-cell counts were taken at the date of initiation of PI therapy. The time 
to the date of the endpoints or the date of the most recent visit was measured. Values 
were plotted and results are presented as the percent of subjects reaching an endpoint. 
Chi-square analyses were performed with any potential confounding variables. 
f 
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Results 
Description of cohort 
The clinic population was comprised of 79 patients. Of these, there were 41 males 
(52%) and 38 females (48%). There were five deaths during the study period. The mean 
age of the subjects was 9.6 years (median 9.1 years; range 2.2-16.6 years). Among all 79 
subjects, the mean drop in viral load was 0.13 log10 copies/mL, the mean rise in absolute 
CD4+ T-cell count was 28 cells/pL, and the mean rise in CD4+ T-cell percentage was 
2%. The mean duration of therapy was 731.2 days. The study measures for all subjects 
are shown in Table 1. 
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Table 1. Study measures: All study subjects (n=79) 
Study measure Mean ± S. D. 
Age (years) 9.600 ±3.610A 
Baseline values 
Baseline viral load log (log,0 copies/mL) 4.215 ± 1.078 
Baseline absolute CD4+ T-cell count (cells/pL) 519.747 ±409.916 
Baseline CD4+ T-cell percentage (%) 19.770 ± 11.058 
Final values 
Final viral load log (log10 copies/mL) 4.087 + 1.310 
Final absolute CD4+ T-cell count (cells/pL) 547.291 ± 358.257 
Final CD4+ T-cell percentage (%) 22.154 ± 11.119 
Differences 
Difference in viral load log (logl0 copies/mL) -0.128 ± 1.239 
Difference in absolute CD4+ T-cell count (cells/pL) 27.544 ±277.408 
Difference in CD4+ T-cell percentage (%) 2.385 ± 7.289 
Total duration of therapy (days) 731.240 ± 228.351 
A All data are expressed as mean ± standard deviation. 
Comparison of protease inhibitor and non protease inhibitor treated subjects 
In order to compare subjects treated with PI therapy to those not treated with PI 
therapy, six subjects who were not taking any medications during the study period were 
excluded. Therefore, 73 subjects were included in the initial analysis comparing those 
who received Pis to those who had never received Pis. There were 40 patients who had 

15 
been treated with Pis. Of these, 5 were excluded because they had experienced treatment 
with Pis for less than 3 weeks. Thus, there were 35 patients who had been treated with 
protease inhibitors for > 3 weeks and 38 patients who had never been treated with 
protease inhibitors. 
The mean age of the PI group was 10.6 years (range 3.9-16.6 years) and of the non- 
PI group was 8.7 years (range 2.2-16.0 years) (p=0.029). The PI group had a mean 
increase in viral load of 0.063 log10 copies/mL while the non-PI group had a mean 
decrease in viral load of 0.29 log10 copies/mL (p=0.26). The PI group exhibited a mean 
increase in absolute CD4+ T-cell count of 118 cells/pL while the non-PI group exhibited 
a mean decrease in absolute CD4+ T-cell count of 42 cells/pL (p=0.027). One subject 
who had a decrease in CD4+ T-cell count of 900 cells/pL was excluded from the analysis 
as it was thought to be an incorrect measurement. The mean rise in CD4+ T-cell 
percentage was 3% for the PI group and 2% for the non PI group (p=0.49). Results of the 
unadjusted analyses are shown in Table 2. 
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Table 2. Unadjusted comparison of protease inhibitor (PI) therapy versus non PI therapy 
PI therapy 
(N=35) 
Non PI therapy 
(N=38) 
P 
value 
Age (years) 10.591 + 3.860A 8.726 ±3.273 0.0287 
Baseline values 
Baseline viral load log (log,0 copies/mL) 4.033 + 1.296 4.230 ±0.896 0.3136 
Baseline absolute CD4+ T-cell count (cells/pL) 318.371 ±351.148 658.921 ±399.135 0.0003 
Baseline CD4+ T-cell percentage (%) 15.594 + 11.251 22.184 ±9.970 0.0098 
Final values 
Final viral load log (log10 copies/mL) 4.096 ± 1.685 4.012 ±0.982 0.7975 
Final absolute CD4+ T-cell count (cells/pL) 436.771 ± 358.977 616.816 ± 352.278 0.0340 
Final CD4+ T-cell percentage (%) 18.549 ± 11.321 23.921 ± 10.106 0.0356 
Differences 
Difference in viral load log (log,0 copies/mL) 0.063 ± 1.633 -0.288 ±0.834 0.2585 
Difference in CD4+ T-cell count (cells/pL) 118.400 ±266.453 -18.919 ± 250.790° 0.0274 
Difference in CD4+ T-cell percentage (%) 2.954 ±8.446 1.737 ±6.652 0.4943 
Total duration of therapy (days) 759.286 ± 171.687 710.053 ±277.479 0.3615 
Duration of PI therapy (days) 464.914 ±274.958 - - 
A All data are expressed as mean + standarc deviation. Significant values are printed in 
bold. 
B N=37, after 1 subject was excluded for an extreme outlying difference in absolute 
CD4+ T-cell count. 
The unadjusted analysis showed that the mean change in absolute CD4+ T-cell 
count was significantly different between the two groups (p=0.027). In contrast, there 
were no significant differences between final and baseline values for viral load (p=0.26) 
or for CD4+ T-cell percentage (p=0.49) when the two treatment groups were compared. 
Table 3 shows the relationship between the outcomes and potential confounding factors. 
Baseline viral load level, baseline absolute CD4+ T-cell count, and baseline CD4+ T-cell 
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percentage were shown to be potential confounders and were thus included in the 
multivariate analysis. The duration of therapy was not found to be correlated with the 
outcomes of interest. 
Table 3. Unadjusted comparison of covariables with outcomes (n=79) 
Covariable Difference in 
viral load 
Difference in 
absolute CD4+ 
T-cell count 
Difference in 
CD4+ T-cell 
percentage 
Age 0.143 0.258 -0.087 
(0.208)A (0.022)B (0.445) 
Baseline viral load -0.367 -0.115 0.124 
(0.001) (0.311) (0.278) 
Baseline CD4+ T-cell count -0.054 -0.513 -0.210 
(0.638) (0.0001) (0.064) 
Baseline CD4+ T-cell percentage 0.090 -0.350 -0.321 
(0.431) (0.002) (0.004) 
Duration of therapy -0.020 0.004 0.009 
(0.864) (0.972) (0.936) 
A Top number represents Pearson correlation coefficient. Number in parentheses 
represents p-value. 
B Significant values are printed in bold. 
The association between PI therapy and difference in viral load was adjusted for 
age, baseline viral load, baseline absolute CD4+ T-cell count, and baseline CD4+ T-cell 
percentage and was still found not to be significant. The results of this analysis are 
shown in Table 4. The only significant predictor was found to be baseline viral load 
(p=0.014). 

Table 4. Multivariate analysis: Association between PI therapy and difference in viral 
load (N=72)_ 
Variable CoefficientA P value 
Protease inhibitor therapy 0.195 0.344 
Age 0.018 0.714 
Baseline viral load log -0.362 0.014B 
Baseline absolute CD4+ T-cell count -0.00048 0.501 
Baseline CD4+ T-cell percentage 0.021 0.393 
A Parameter estimate for best-fit line. 
B Significant values are printed in bold. 
The association between PI therapy and difference in absolute CD4+ T-cell count 
was adjusted for age, baseline viral load, baseline absolute CD4+ T-cell count, and 
baseline CD4+ percentage and was no longer found to be significant. The results of this 
analysis are shown in Table 5. The baseline absolute CD4+ T-cell count was the only 
significant predictor (p=0.034). 
Table 5. Multivariate analysis: Association between PI therapy and difference in 
absolute CD4+ T-cell count (N=72) __ 
Variable CoefficientA P value 
Protease inhibitor therapy 46.514 0.477 
Age -3.122 0.748 
Baseline viral load log -22.341 0.447 
Baseline absolute CD4+ T-cell count -0.336 0.034B 
Baseline CD4+ T-cell percentage 2.077 0.679 
A Parameter estimate for best-fit line. 
B Significant values are printed in bold. 

The association between PI therapy and CD4+ T-cell percentage was adjusted for 
age, baseline viral load, baseline absolute CD4+ T-cell count, and baseline CD4+ T-cell 
percentage and was still not found to be significant (see Table 6). The only significant 
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predictor was baseline CD4+ T-cell percentage (p=0.039). 
Table 6. Multivariate analysis: Association between PI therapy and difference in CD4+ 
percentage (N=72)__ 
Variable CoefficientA P value 
Protease inhibitor therapy 0.117 0.950 
Age -0.408 0.149 
Baseline viral load log -0.156 0.853 
Baseline absolute CD4+ T-cell count 0.00043 0.918 
Baseline CD4+ T-cell percentage -0.298 0.039B 
A Parameter estimate for best-fit line. 
B Significant values are printed in bold. 
In summary, after adjusting for several baseline factors, there were no significant 
differences between the subjects treated with Pis and the subjects not treated with Pis 
with respect to viral load, absolute CD4+ T-cell count, and CD4+ T-cell percentage 
outcomes. 
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Description of protease inhibitor treated subjects 
Forty subjects had been treated with protease inhibitors. Of the five that had been 
previously excluded due to less than 3 weeks of PI therapy, one subject had since been 
followed up and was added to the analysis. Five additional subjects were excluded 
because there were no viral load and CD4+ T-cell count measurements recorded prior to 
the initiation of PI therapy. Thus, 31 subjects who had at least one baseline measurement 
prior to initiation of Pis and at least one follow-up measurement were included in the 
secondary analysis of subjects treated with Pis. These subjects were examined in order to 
assess whether prior antiretroviral medication history affected the results of PI therapy. 
The mean age of all patients who had been treated with protease inhibitors was 8.6 
years (range 2.0-15.7 years). At the time of initiation of PI therapy, the mean viral load 
for all subjects was 4.19 log10 copies/mL and the mean absolute CD4+ T-cell count was 
391 cells/pL. Table 7 shows the baseline characteristics for all subjects who were treated 
with PI therapy. Of the PI treated subjects, 7 (22.6%) achieved undetectable viral load 
levels at some point following the initiation of Pis. The median time to undetectable viral 
load was 10.9 weeks after PI initiation (range 4.6-109.0 weeks). 
Table 7. Baseline characteristics: All subjects treated with Pis (n=31) 
Characteristic Mean + S. D. 
Age (years) 8.58 + 4.01A 
Baseline viral load log (log10 copies/mL) 4.19 ± 1.53 
Baseline absolute CD4+ T-cell count (cells/pL) 391.00 ±406.84 
A All data are expressed as mean + standard deviation. 
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The 31 subjects who had received PI therapy were divided into two groups based on 
their treatment history prior to the initiation of PI therapy. The “treatment inexperienced” 
group, referred to henceforth as the “dual therapy group”, was comprised of 20 subjects 
who were on dual therapy just prior to PI initiation, one subject who was on monotherapy 
and two who were treatment naive. The “treatment experienced” group, referred to 
henceforth as the “triple therapy” group, was comprised of 8 subjects who had been 
treated with triple therapy just prior to initiation of Pis. Table 8 shows the baseline 
characteristics of the two groups. The mean age for the “dual therapy” group was 9.0 
years (range 2.0-15.7 years) and for the “triple therapy” group was 7.5 years (range 2.0- 
15.4 years) (p=0.37). The baseline viral load was 4.25 logl0 copies RNA/mL for the 
“dual therapy” group and 4.03 log,0 copies RNA/mL for the “triple therapy” group 
(p=0.74). The baseline absolute CD4+ T-cell count was 333 cells/pL for the “dual 
therapy” group and 558 cells/pL for the “triple therapy” group (p=0.18). 
Table 8. Comparison of baseline characteristics of groups 
Characteristic Dual therapy 
Group (N=23) 
Triple therapy 
group (N=8) 
P value 
Age (years) 8.97 + 3.82A 7.48 + 4.59 0.37 
Baseline viral load log (log10 copies/mL) 4.25 + 1.47 4.03 ± 1.79 0.74 
Baseline CD4+ T-cell count (cells/pL) 333.09 ±362.97 557.50 ±502.61 0.18 
Clinical category N 2 (8.7%) 0 0.39 
Clinical category A 4(17.3%) 3 (37.5%) 0.24 
Clinical category B 5 (21.7%) 2 (25.0%) 0.85 
Clinical category C 12(52.1%) 3 (37.5%) 0.47 
A All data are expressed as mean ± standarc deviation. 
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Virologic responses among protease inhibitor treated subjects 
Figure 1 shows the rates of achieving a 0.5 log drop in viral load in the “dual 
therapy” and “triple therapy” groups. Those in the “dual therapy” group achieved a drop 
of > 0.5 log in viral load levels more rapidly than those in the “triple therapy” group (log 
rank p=0.052). At 12 months, 53.8% of the “dual therapy” group had demonstrated a > 
0.5 log drop in viral load, as compared with 14.3% in the “triple therapy” group. At 24 
months, 63% of the “dual therapy” group and 14.3% of the “triple therapy” group had 
achieved this endpoint. In total, 13 of 23 (56.5%) in the “dual therapy” group and 1 of 8 
(12.5%) in the “triple therapy” group achieved a significant drop in viral load. 
Figure 1 
Probability of achieving 0.5 log drop in viral load 
Dual therapy 
group 
Triple therapy 
group 
10 15 20 25 30 35 
Time since start of protease inhibitors 
(months) 
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The effect of baseline viral load on the rate of achieving a > 0.5 log drop in viral 
load was examined. The “dual therapy” group was divided into two subgroups: those 
whose baseline viral loads were less than or equal to the median of 4.2 log,0 copies/mL, 
and those whose baseline viral loads were greater than the median. Figure 2 shows the 
comparison of the two subgroups within the “dual therapy” group. The rate of achieving 
a significant drop in viral load was similar in the two groups (log rank p=0.70). At 12 
months, 51.4% of those with a lower baseline viral load had demonstrated a drop in viral 
load, as compared with 56.4% of those with a higher baseline viral load. 
Figure 2 
Probability of achieving 0.5 log drop in viral load 
Dual therapy group only 
0 5 10 15 20 25 30 35 
—♦—Baseline viral 
load <= 4.2 
—s—Baseline viral 
load >4.2 
Time since start of protease inhibitors 
(months) 
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Immunologic responses among protease inhibitor treated subjects 
Figure 3 shows the rates of achieving a rise of > 50 cells in absolute CD4+ T-cell 
count in the “dual therapy” and “triple therapy” groups. Those in the “triple therapy” 
group achieved a significant rise in CD4+ T-cell count more rapidly than those in the 
“dual therapy” group (log rank p=0.030). At 12 months, 100% of the “triple therapy” 
group and 53.4% of the “dual therapy” group had demonstrated a significant rise in 
CD4+ T-cell count. In total, 15 of 23 (65.2%) in the “dual therapy” group and 8 of 8 
(100%) in the “triple therapy” group achieved a significant rise in CD4+ T-cell count. 
Figure 3 
Probability of achieving CD4+ T-cell count 
increase of 50 
Dual therapy 
group 
Triple therapy 
group 
Time since start of protease inhibitors 
(months) 
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The effect of the baseline CD4+ T-cell count on the success of the therapy was 
examined. The “dual therapy” group was divided into two subgroups: those whose 
baseline CD4+ T-cell counts were less than or equal to the median of 230 cells/pL, and 
those whose baseline CD4+ T-cell counts were greater than the median. Figure 4 shows 
the comparison of these two subgroups. The group with a higher mean baseline CD4+ T- 
cell count achieved a rise of > 50 cells/pL faster, when compared with those with lower 
mean baseline CD4+ T-cell counts (log rank p=0.034). At 12 months, 81.8% of the 
higher baseline and 41.7% of the lower baseline groups had achieved this endpoint. 
Figure 4 
Probability of achieving CD4+ T-cell count 
increase of 50 
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Effect of clinical category on outcomes 
The possible confounding effect of clinical category was explored by examining 
any possible relationship between clinical category and treatment group or outcome. 
Subjects were divided into two groups based on their CDC clinical category at the time of 
initiation of protease inhibitor therapy: one group comprised of subjects in categories N 
or A and one group comprised of subjects in categories B or C. There was no association 
between clinical category and treatment group (p=0.54). Figure 5 shows the rates of 
decreasing viral load among the N/A and B/C groups. There was no difference in the rate 
of achieving a significant drop in viral load between the two groups (log rank p=0.35). 
Figure 5 
Probability of achieving 0.5 log drop in viral load 
Clinical class 
0 5 10 15 20 25 30 35 
—♦—Clinical class 
N or A 
—0— Clinical class 
B or C 
Time since start of protease inhibitors 
(months) 
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Figure 6 shows the rates of increasing CD4+ T-cell count between the two groups. 
There was no difference in the rate of achieving a significant rise in CD4+ T-cell count 
between the two groups (log rank p=0.07). Thus, clinical category had no effect on the 
differing rates of achieving a significant drop in viral load or a significant rise in CD4+ 
T-cell count when the “dual therapy” and “triple therapy” groups were compared. 
Figure 6 
Probability of achieving CD4+ T-cell count 
increase of 50 
Clinical class 
Time since start of protease inhibitors 
(months) 
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Discussion 
Protease inhibitor versus non protease inhibitor treated subjects 
The present study did not detect any statistically significant improvement over the 
long term among Pi-treated subjects as compared with non-PI-treated subjects in viral 
load and CD4+ T-cell percentage even after controlling for baseline values. There was a 
significantly greater rise in absolute CD4+ T-cell count among the Pi-treated subjects, 
however the outcomes became similar between the two cohorts after controlling for 
baseline values. 
The Pi-treated group was exposed to PI therapy for a mean of 465 days, which 
represents a longer follow-up period than many previously reported studies. The failure 
to detect a difference in outcomes between the PI and non-PI treated groups may 
represent a lack of benefit over time for PI therapy in children. It may also reflect the 
general observation that pediatric patients are less likely to achieve suppression of viral 
load to undetectable levels when compared with adults (23). Some have suggested that 
the virus that replicates in children in the face of PI therapy in children may not have the 
same pathogenic potential as virus isolated from those not on Pis (23). Pis may be 
effective in suppressing “virulent” strains of HIV in children; however, overall viral load 
levels may remain high. 
To date, studies in children have generally demonstrated a moderate improvement 
in viral load with PI therapy over a relatively short period of follow-up of less than 6 
months. For example, the observed rates of complete viral suppression in children on 
protease inhibitors have been variable, ranging from 9% to 60% (15). 
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Pediatric AIDS Clinical Trials Group (PACTG) 338 is the largest study of PI 
therapy thus far. The study enrolled 298 pediatric patients with stable disease (no new 
CDC category within previous 12 months) and mild immunologic suppression 
(immunologic categories 1 or 2), randomized to receive zidovudine/lamivudine, 
zidovudine/lamivudine/ritonavir, or stavudine/ritonavir. Preliminary analyses, after 12 
weeks, have shown a significantly greater proportion of subjects achieving undetectable 
HIV-RNA levels among the ritonavir-treated groups than among those not treated with 
ritonavir (12). 
Purswani et al. compared the effect of changes involving one, two or three 
antiretroviral medications in 54 patients (24). The changes involved addition of NRTIs 
and Pis. The study found that reduction of viral load by > 100-fold or to undetectable 
levels was more likely in children switched to Pis (11 of 21) than in those not receiving 
Pis (1 of 8) (p=0.05). The authors concluded that children switched to Pis as part of a 
change in therapy had a better response than those who did not receive Pis. 
Rutstein et al. examined the short-term effects of protease inhibitor therapy on 28 
HIV-infected children followed for a mean of 6 months (18). They found that the 
majority of the subjects (92.8%) experienced a significant decrease in viral load and 
increase in CD4+ T-lymphocyte counts, defined as a drop of greater than 0.5 log10 
copies/mL in viral load or an increase of greater than 50 cells/pL in CD4+ T-cell count. 
Seven of the patients sustained viral suppression for a mean period of 6 months. 
Melvin et al. examined 9 patients who were treated with combination therapy 
including protease inhibitors (17). All patients were previously treated with multiple 
reverse transcriptase inhibitors. They observed a decrease in the HIV-RNA levels in all 

patients within 3 to 4 weeks. However one-third of the patients exhibited a rebound 
increase of Pi-resistant HIV within 26 weeks. 
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Wintergerst et al. examined the effects of two antiretroviral triple combinations, 
both including the protease inhibitor indinavir, on viral load and CD4+ T-cell counts 
(19). Fifteen patients, with extensive prior antiretroviral therapy, were placed on either 
zidovudine/lamivudine/indinavir (Group A) or stavudine/lamivudine/indinavir (Group 
B). Both groups displayed decreases in viral load and increases in CD4+ T-cell count 
during the six month follow-up period. The investigators observed an increase in CD4+ 
T-cell count in almost all patients, even those with insufficient suppression of viral load. 
They postulated that the incomplete viral suppression was due to prior medication 
experience. 
To date, there have been a few small studies of the safety and efficacy of ritonavir. 
Thuret et al. studied 22 children who were treated with triple therapy including ritonavir 
(15). Seven of the 22 subjects achieved and maintained undetectable viral loads 
throughout the 18 month duration of the study. Of the remaining 15, seven had a 
transient drop in viral load of at least 1 logic copies/mL and eight exhibited a decline of 
less than 1 log10 copies/mL. The subjects demonstrated a significant and linear increase 
in their CD4+ T-cell counts over 12 months, independent of their viral load response. In 
another small study of the effects of ritonavir therapy in children with advanced HIV 
infection, all eight of the subjects experienced a decrease in viral load, although a 
maximal response was seen only after 12 months of treatment (16). 
Limited studies with nelfmavir in combination with reverse transcriptase inhibitors 
have shown significant decreases in HIV-RNA levels (12, 14). Krogstad et al. found that 
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39 of 55 children (71 %) treated with nelfinavir achieved a decrease in viral load of at 
least 0.7 log,0 copies/mL. However, in 17 of the 39 responders, the response was 
transient, and the viral load returned to within 0.7 log,0 copies/mL of baseline after a 
median of 5 weeks. In 22 of the 39, however, the reduction was sustained through the 
remainder of their follow-up (median 40 weeks). 
These studies had several limitations which necessitate careful interpretation of the 
results. Many, like the present one, were retrospective analyses which were not 
randomized (15, 18, 24). Most involved small numbers of subjects (12, 14, 15, 19). The 
length of follow-up was often less than 6 months. In addition, many of the studies did 
not have a control group with which to compare the magnitude of response (12, 14, 15, 
18, 19). In the studies that involved only subjects with mild disease, it is unclear how 
generalizable the results would be to patients with more severe disease and higher viral 
load burdens (12). The present study, although it involved small numbers of subjects, 
included a longer period of follow-up after initiation of Pis. Our having failed to 
demonstrate an effect on surrogate markers when we compared Pi-treated to non-PI 
treated subjects should be interpreted cautiously, considering the limitations which will 
be discussed below. 
Virologic outcome in protease inhibitor treated subjects 
When the two groups of subjects who were treated with Pis were compared, the 
“dual therapy” group experienced greater success in achieving a significant drop in viral 
load after starting PI therapy than the “triple therapy” group. This improvement was not 
likely affected by baseline viral load, as individuals in the “dual therapy” group with 
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lower and higher baseline viral loads had similar rates of decline. In addition, there was 
no difference between the “dual therapy” and “triple therapy” groups with respect to their 
baseline viral loads. Thus the greater success achieved by the “dual therapy” group was 
likely attributable to the difference in antiretroviral medication experiences prior to PI 
therapy. Those individuals who had been treated with triple therapy may have 
accumulated more viral resistance and thus were less susceptible to the therapeutic action 
of Pis. 
It is, however, still unclear why other antiretroviral experience would affect the 
efficacy of PI therapy, as the mutations among classes of drugs do not seem to overlap. It 
is possible that exposure to more antiretrovirals predisposes patients to the development 
of greater viral pathogenicity, broader resistance to antiretroviral agents, wider 
entrenchment of virus in sanctuary sites, or other changes that develop with prolonged 
HIV infection (14). 
Immunologic outcome in protease inhibitor treated subjects 
In contrast to the viral load response, the “triple therapy” group displayed greater 
success in achieving a significant rise in CD4+ T-cell count. When the effect of baseline 
CD4+ T-cell count was examined, those individuals with a higher CD4+ T-cell count 
were more likely to achieve an increase in numbers of CD4+ T-cells. The greater 
response of the “triple therapy” group to PI therapy may have been due to their higher 
baseline CD4+ T-cell counts (558 versus 333 cells/pL). Although this difference in 
numbers of baseline CD4+ T-cells was not statistically significant, possibly due to the 
small sample size, the differences may have been clinically significant. Thus, the 
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apparent effect of Pis on CD4+ T-cell count was possibly determined by baseline CD4+ 
T-cell levels. Subjects with better immunologic status at the start of PI therapy appeared 
to have had a better response to Pis. 
In general, children exhibit a more consistent and a greater degree of CD4+ T-cell 
reconstitution when compared with adults, even when treated with single antiretroviral 
agents (15, 23, 25). This response has been noted with protease inhibitor therapy, even 
when viral load responses are minimal. Sleasman et al. demonstrated that reconstitution 
of CD4+ T-cells occurred even among children who did not have viral suppression in 
response to ritonavir (23). An increasing CD4+ T-cell count is an encouraging 
prognostic sign, as studies in both children and adults suggest that higher CD4+ T-cell 
counts reduce the risk of acquiring AIDS defining illnesses and, hence, of HIV disease 
progression. In children, PI therapy may be effective in maintaining immunologic status 
and slowing disease progression, independent of its effect on viral load. 
Regeneration of T-cells occurs either by redistribution of primed and unprimed T- 
cells or by development and selection of new unprimed T-cells from the thymus (15). In 
adults on highly active antiretroviral therapy, the initial rise in CD4+ T-cell counts 
appears to be predominantly a result of cell redistribution from lymphoid organs. HIV-1 
infection is thought to result in lymphocyte trapping in lymphoid tissues. Suppression of 
viral replication then allows release of these lymphocytes into the circulation (23). In 
children, however, part of the initial increase in CD4+ T-cells is thought to be due to 
increased thymic output of newly generated naive CD4+ T-cells. This is consistent with 
the well-recognized residual thymic activity that occurs in children (23, 26). 
Antiretroviral therapy may also reduce the sensitivity of T-cells to apoptosis (26). This 

combination of increased thymopoesis and decreased apoptosis may lead to more 
effective immune reconstitution in children. 
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Higher CD4+ T-cell counts at baseline confer a greater ability for regeneration of T- 
cells and thus appear to promote a better response to antiretrovirals. Krogstad et al. 
demonstrated that prolonged suppression of plasma viremia was observed more often in 
patients with higher baseline CD4+ T-cell counts (14). Thuret et al. observed a 
paradoxically greater increase in CD4+ T-cell count in children with higher initial viral 
loads, indicating that viral load and CD4+ T-cell counts are not always congruent 
prognostic factors in children (15). 
Thus, this study supports the observation that PI therapy may be more effective in 
contributing to immune reconstitution than in suppressing viral load in children. For this 
reason. Pis are indicated in children as a therapeutic option to facilitate CD4+ T-cell 
regeneration and, thus, to minimize disease progression. This study also supports the 
practice of initiating PI therapy early in the course of the disease. Those individuals with 
less prior exposure to antiretrovirals and with better immunologic status at the start of PI 
therapy were more likely to achieve a drop in viral load and a rise in CD4+ T-cell count 
after the initiation of PI therapy. 
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Conclusions 
Summary of findings 
In summary, there was no overall difference over a mean follow-up time of 84 
weeks between Pi-treated and non-PI treated subjects with respect to surrogate markers 
of infection, including viral load, absolute CD4+ T-cell count, and CD4+ T-cell 
percentage. When comparing the rates of success after initiating PI therapy, the “dual 
therapy” group had a faster rate of decline in viral load than the “triple therapy” group. 
This may be attributed to less prolonged exposure to other antiretroviral drugs and, 
potentially, less viral resistance. After starting PI therapy, the “triple therapy” group had 
a faster rate of rise in CD4+ T-cell count, most likely due to their higher baseline CD4+ 
T-cell counts. Thus, although the long term efficacy of PI therapy remains unclear, there 
is support for the use of this class of antiretrovirals early in the course of HIV disease in 
children. 
Limitations of study 
There are several limitations to the present study which must be considered. The 
study was not a controlled clinical trial, but rather reflects experience with antiretroviral 
therapy in a natural clinical situation. While this provides important information for 
clinical decision making, it does not allow for the equalization of subject groups provided 
by randomization. This was a retrospective cohort study which introduces potential bias 
in the classification of subjects. Medication decisions were made on the basis of clinical 
judgment, which influences the group to which each subject was assigned. 
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While larger than some of the other reported studies, the sample size of 79 subjects 
was still small and the study may have lacked statistical power to detect true differences 
between the Pi-treated and non-PI treated groups. In addition, the comparison groups 
were comprised of heterogeneous populations with varying degrees of disease severity. 
Subjects were also treated with a multiplicity of regimens for different lengths of time 
and were followed up at varying intervals. 
Compliance with the medication regimens was not assessed. While compliance is 
difficult to ascertain and quantify, it represents an important factor in the success of the 
therapy and more attempts should be made to include this variable in future studies. 
In comparing the PI and non-PI treated groups, the follow-up times for subjects 
varied widely and thus there may have been a maximal effect of therapy in the weeks 
following the start of therapy which then diminished over time. Subjects on PI therapy 
may have experienced a rebound increase in viral resistant strains, thus obscuring any 
initial benefits of the Pis. Future analyses of this cohort of patients will compare subjects 
treated with Pis to those not treated with Pis within 12 to 24 weeks of starting therapy, in 
order to assess the initial effects of PI therapy. 
Since the value of surrogate laboratory markers in assessing prognosis and response 
to therapy is still under study in children, clinical outcomes should also be examined. A 
limitation of this study is that it did not include any clinical endpoints, such as 
development of opportunistic infections. However, as in most of the AIDS clinical trials, 
the number of patients who died or developed opportunistic infections was not large 
enough to provide the necessary statistical power for analysis. 
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Another limitation of the study was the insufficient number of subjects on no 
therapy or monotherapy prior to starting Pis. The division of groups treated with Pis into 
“dual therapy” and “triple therapy” may have minimized differences between the two 
cohorts. Further analysis, with greater numbers of subjects on no therapy and 
monotherapy before initiation of Pis, may provide more information about prior 
antiretroviral experience. In addition, the regimen at the time of starting Pis was used as 
a surrogate for the entire antiretroviral experience which may not be valid. Future studies 
may look at the effect of entire medication history on the efficacy of Pis. 
This study did not examine how long effects were sustained after starting Pis 
between the “dual therapy” and “triple therapy” groups. We used the first date of 
reaching an endpoint in the analysis but did not assess further measurements. Future 
studies should examine the mean length of time after Pis are started until viral rebound or 
CD4+ T-cell decline. 
Conclusions of study 
In conclusion, this study provides an assessment of the clinical experience with Pis 
in a cohort of HIV-infected children, most of whom had prior antiretroviral experience. 
While the effects of Pis on surrogate markers of infection were moderate, there did 
appear to be some benefit to using these therapies in HIV-infected children. If utilized, 
they should be introduced into the therapeutic regimen early in the course of disease, 
while prior antiretroviral experience is minimal and immune status is stable. Effective 
antiretroviral therapy in children may involve immune reconstitution even without 
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maximal viral load suppression. Further studies of Pis in children will elucidate the role 
of Pis in therapy for HIV disease. 
Recommendations for future research 
Additional studies are needed with randomized subject groups and longer follow-up 
to evaluate the efficacy of these antiretroviral medications in children. A few larger 
prospective studies are already in progress which are examining the effect of initiating 
protease inhibitors early on disease outcome. PACTG 356 is a multicentered trial 
examining a triple-drug regimen (zidovudine/lamivudine/nevirapine) and two quadruple- 
drug regimens (zidovudine/lamivudine/nevirapine/abacavir and 
stavudine/lamivudine/nevirapine/nelfmavir) in children aged 2 weeks to 2 years.(8) 
PACTG 345 is a multicentered trial examining a triple-drug regimen 
(zidovudine/lamivudine/ritonavir) in children aged 4 weeks to 2 years. 
Future studies should also examine the long term effects of Pis on viral loads, 
CD4+ T-cell counts and disease outcomes. Long term natural history studies will 
provide important information on the efficacy of these medications. As the duration and 
quality of life for children with HIV are improved, additional study will continue to 
provide guidelines for the most effective management of children. 
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Appendices 
Appendix 1 
Recommended antiretroviral regimens for initial therapy for human immunodeficiency 
virus (HIV) infection in children (13, 22) 
Preferred Regimen 
Evidence of clinical benefit and sustained suppression of HIV RNA in clinical trials in 
HIV-infected adults; clinical trials in HIV-infected children are ongoing. 
• One highly active protease inhibitor plus two nucleoside analogue reverse 
transcriptase inhibitors (NRTIs) 
o Preferred protease inhibitor for infants and children who cannot swallow pills or 
capsules: nelfinavir or ritonavir. Alternative for children who can swallow pills 
or capsules: indinavir. 
o Recommended dual NRTI combinations: the most data on use in children are 
available for the combinations of zidovudine (ZDV) and dideoxyinosine (ddl) and 
for ZDV and lamivudine (3TC). More limited data are available for the 
combinations of stavudine (d4T) and ddl, d4T and 3TC, and ZDV and zalcitabine 
(ddC). 
• Alternative for children who can swallow capsules: Efavirenz (sustiva) plus 2 NRTIs 
(see above) or efavirenz (sustiva) plus nelfinavir and 1 NRTI. 
Alternative Regimen 
Less likely to produce sustained HIV RNA suppression in infected adults; the 
combination of nevirapine, ZDV, and ddl produced substantial and sustained suppression 
of viral replication in two of six infants first treated at age <4 months. 
• Nevirapine and two NRTIs 
Secondary Alternative Regimen 
Clinical benefit demonstrated in clinical trials involving infected adults and/or children, 
but initial viral suppression may not be sustained. 
• Two NRTIs 
Not Recommended 
Evidence against use because of overlapping toxicity and/or because use may be 
virologically undesirable. 
• Any monotherapy 
• d4T and ZDV 
• ddC and ddl 
• ddC and d4T 
• ddC and 3TC 
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Appendix 2 
Pediatric human immunodeficiency virus classification (27) 
Clinical categories 
Immunologic 
categories 
N: No 
signs/symptoms 
A: Mild 
signs/symptoms 
It: Moderate 
signs/symptoms 
C: Severe 
signs/symptoms 
1: No evidence of 
suppression 
N1 At B1 Cl 
2: Evidence of 
moderate 
suppression 
N2 A2 B2 C2 
3: Severe 
suppression 
N3 A3 B3 C3 
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Appendix 3 
1994 Revised human immunodeficiency virus pediatric classification system immune 
categories based on age-specific CD4+ T-lymphocyte count and percentage (13) 
< 12 months 1-5 years 6-12 years 
Immune category No./pL (%) No./pL (%) No./pL (%) 
Category 1- 
no suppression 
>1,500 (>25%) >1,000 (>25%) >500 (>25%) 
Category 2- 
moderate 
suppression 
750-1,499 (15-24%) 500-999 (15-24%) 200-499 (15-24%) 
Category 3- 
severe suppression 
<750 (<15%) <500 (<15%) <200 (< 15%) 
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Appendix 4 
1994 Revised human immunodeficiency virus pediatric classification system: clinical 
categories (13) (27) 
Category N: Not Symptomatic 
Children who have no signs or symptoms considered to be the result of HIV infection or 
who have only one of the conditions listed in category A. 
Category A: Mildly Symptomatic 
Children with two or more of the following conditions but none of the conditions listed in 
categories B and C: 
• Lymphadenopathy (>0.5 cm at more than two sites; bilateral=one site) 
• Hepatomegaly 
• Splenomegaly 
• Dermatitis 
• Parotitis 
• Recurrent or persistent upper respiratory infection, sinusitis, or otitis media 
Category B: Moderately Symptomatic 
Children who have symptomatic conditions other than those listed for category A or 
category C that are attributed to HIV infection. Examples of conditions in clinical 
category B include but are not limited to the following: 
• Anemia (<8 gm/dL), neutropenia (< 1,000/mm3), or thrombocytopenia (<100,000/ 
mm3) persisting >30 days 
• Bacterial meningitis, pneumonia, or sepsis (single episode) 
• Candidiasis, oropharyngeal (i.e. thrush) persisting for >2 months in children aged 6 
months 
• Cardiomyopathy 
• Cytomegalovirus infection with onset before age 1 month 
• Diarrhea, recurrent or chronic 
• Hepatitis 
• Herpes simplex virus (HSV) stomatitis, recurrent (i.e. more than two episodes within 
1 year) 
• HSV bronchitis, pneumonitis, or esophagitis with onset before age 1 month 
• Herpes zoster (i.e. shingles) involving at least two distinct episodes or more than one 
dermatome 
• Leiomyosarcoma 
• Lymphoid interstitial pneumonia (LIP) or pulmonary lymphoid hyperplasia complex 
• Nephropathy 
• Nocardiosis 
• Fever lasting >1 month 
• Toxoplasmosis with onset before age 1 month 
• Varicella, disseminated (i.e. complicated chickenpox) 
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Category C: Severely Symptomatic 
Children who have any condition listed in the 1987 surveillance case definition for 
acquired immunodeficiency syndrome, with the exception of LIP (which is a category B 
condition) 
• Serious bacterial infections, multiple or recurrent (i.e. any combination of at least two 
culture-confirmed infections within a 2-year period) of the following types: 
septicemia, pneumonia, meningitis, bone or joint infection, or abscess of an internal 
organ or body cavity (excluding otitis media, superficial skin or mucosal abscesses, 
and indwelling catheter-related infections) 
• Candidiasis, esophageal or pulmonary (bronchi, trachea, lungs) 
• Coccidioidomycosis, disseminated (at site other than or in addition to lungs or 
cervical or hilar lymph nodes) 
• Cryptococcosis, extrapulmonary 
• Cryptosporidiosis or isosporiasis with diarrhea persisting >1 month 
• Cytomegalovirus disease with onset of symptoms at age >1 month (at a site other 
than liver, spleen, or lymph nodes) 
• Encephalopathy (at least one of the following progressive findings present for at least 
2 months in the absence of a concurrent illness other than HIV infection that could 
explain the findings): a) failure to attain or loss of developmental milestones or loss 
of intellectual ability, verified by standard developmental scale or neuropsychological 
tests; b) impaired brain growth or acquired microcephaly demonstrated by head 
circumference measurements or brain atrophy demonstrated by computerized 
tomography or magnetic resonance imaging (serial imaging is required for children 
<2 years of age); c) acquired symmetric motor deficit manifested by two or more of 
the following: paresis, pathologic reflexes, ataxia, or gait disturbance 
• Herpes simplex virus infection causing a mucocutaneous ulcer that persists for >1 
month; or bronchitis, pneumonitis, or esophagitis for any duration affecting a child >1 
month of age 
• Histoplasmosis, disseminated (at a site other than or in addition to lungs or cervical or 
hilar lymph nodes) 
• Kaposi’s sarcoma 
• Lymphoma, primary, in brain 
• Lymphoma, small, noncleaved cell (Burkitt’s), or immunoblastic or large cell 
lymphoma of B-cell or unknown immunologic phenotype 
• Mycobacterium tuberculosis, disseminated or extrapulmonary 
• Mycobacterium, other species or unidentified species, disseminated (at a site other 
than or in addition to lungs, skin, or cervical or hilar lymph nodes) 
• Mycobacterium avium complex or Mycobacterium kansasii, disseminated (at site 
other than or in addition to lungs, skin, or cervical or hilar lymph nodes) 
• Pneumocystis carinii pneumonia 
• Progressive multifocal leukoencephalopathy 
• Salmonella (nontyphoid) septicemia, recurrent 
• Toxoplasmosis of the brain with onset at >1 month of age 
• Wasting syndrome in the absence of a concurrent illness other than HIV infection that 
could explain the following findings: a) persistent weight loss >10% of baseline OR 
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b) downward crossing of at least two of the following percentile lines on the weight- 
for-age chart (e.g. 95th, 75th, 50th, 25th, 5th) in a child >1 year of age OR c) <5th 
percentile on weight-for-height chart on two consecutive measurements, >30 days 
apart PLUS a) chronic diarrhea (i.e. at least two loose stools per day for >30 days) 
OR b) documented fever (for >30 days, intermittent or constant) 
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